Bone marrow-derived mononuclear cells for critical limb ischemia

This study aims to assess the efficacy of cell concentrates from bone marrow, processed with the point of care technology Res-Q® 60 BMC, in treating critical limb ischemia and peripheral artery disease patients. After 12 months, 85.7% of the patients had not required amputation and showed measurable improvement in blood flow and in pain scores.